20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Difelikefalin in Focus: Advancing Treatments for Chronic Itch

At NINGBO INNO PHARMCHEM CO.,LTD., we are constantly exploring advanced chemical entities that can lead to significant improvements in patient care. Difelikefalin, a sophisticated peptide therapeutic, represents a major stride in addressing chronic itch conditions.

Difelikefalin is characterized by its role as a selective kappa opioid receptor (KOR) agonist. Unlike conventional opioid medications, its key advantage lies in its peripheral restriction. This means it primarily acts on receptors outside the central nervous system, effectively bypassing common side effects like drowsiness, confusion, and respiratory depression associated with central opioid action. This makes it an ideal candidate for conditions where long-term management is necessary.

The primary therapeutic application highlighted for Difelikefalin is in the treatment of pruritus associated with chronic kidney disease (CKD-aP). The debilitating nature of this itch significantly impacts patients' lives. NINGBO INNO PHARMCHEM CO.,LTD. understands the importance of providing compounds that offer genuine relief. Difelikefalin's ability to modulate itch pathways through peripheral KOR activation is central to its success in clinical settings. Its efficacy has been well-documented, showing significant reductions in itching and improvements in sleep and overall quality of life.

Beyond its use in CKD-aP, the research into difelikefalin uses extends to other potential pain management applications. Its selective action makes it a valuable tool for exploring novel therapeutic strategies for conditions characterized by pain and inflammation. The ongoing advancements in understanding difelikefalin side effects continue to build confidence in its therapeutic profile, emphasizing its relative safety compared to other opioid receptor modulators.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying high-quality materials for pharmaceutical development. Our focus on compounds like Difelikefalin reflects our dedication to supporting innovations in drug discovery and treatment. As research progresses, the exploration of its role as a selective kappa opioid receptor agonist and its impact on kidney disease itching relief continues to highlight its significance in modern medicine.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: The Science of Relief: How Difelikefalin Targets Itch

Next: The Clinical Journey of Difelikefalin: From Lab to Patient

All Rights Reserved